The Claim
Among adults with type 2 diabetes initiating injectable therapy, GLP-1 receptor agonists are associated with a 41% lower hazard of myocardial infarction and a 33% lower hazard of hospitalization for heart failure compared to basal insulin over a median follow-up of 24 months, independent of baseline cardiovascular disease status.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes who start injectable diabetes medication, those using GLP-1 receptor agonists have a lower risk of having a heart attack or being hospitalized for heart failure compared to those using basal insulin, over a period of about two years, regardless of whether they had prior heart disease.
See the scientific wording
Among adults with type 2 diabetes initiating injectable therapy, GLP-1 receptor agonists are associated with a 41% lower hazard of myocardial infarction and a 33% lower hazard of hospitalization for heart failure compared to basal insulin over a median follow-up of 24 months, independent of baseline cardiovascular disease status.
GLP-1 receptor agonists help the heart use energy more efficiently and reduce swelling in blood vessels, which lowers the risk of heart attacks and heart failure.
What the research says
1 studyPeople with type 2 diabetes who started a GLP-1 drug had fewer heart attacks and heart failure hospitalizations than those who started insulin, even if they hadn’t had heart problems before. This suggests GLP-1 drugs may be better for heart health.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.